Immunomodulatory Effects Of Vitamin D: Implications For The Treatment Of Graft Versus Host Disease

Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute), Zhiyu Wu(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Brett Glotzbecker(Dana-Farber Cancer Institute), Whitney Keefe(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Corrine Zarwan(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Jennifer Levine(Cornell University), D Kufe, D. Tzachanis(Beth Israel Deaconess Medical Center)
Transplantation and Cellular Therapy
January 23, 2009
10.1016/j.bbmt.2008.12.403
Cited by 2

Related Papers

PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k